Azenta Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Azenta Business Model Canvas: Clear Insights for Investors & Strategists
Explore Azenta's business model through a focused Business Model Canvas-see how its sample management, genomic services, and automated systems create value, support critical research workflows, and generate revenue across the life sciences market.
Partnerships
Strategic Academic Collaborations
Azenta partners with top universities and research centers-including collaborations yielding 12 peer-reviewed studies in 2024-to secure early access to genomic advances and sample-management methods, feeding a pipeline that accelerated three product integrations in 2023 and helped sustain a 7% R&D efficiency gain year-over-year.
Specialized Cold Chain Logistics Providers
Azenta partners with specialized cold-chain logistics firms offering -80°C to cryogenic transport and validated cold boxes, ensuring sample viability and regulatory compliance (GDP/GxP); in 2024 Azenta reported >30% of shipments using such providers, cutting transit loss below 0.5% and enabling 45+ country reach.
Technology and Software Integrators
Azenta partners with software developers and hardware component makers to embed its automated storage and data-management systems into lab ecosystems and electronic lab notebooks, boosting sample-tracking and genomic analysis capabilities; in 2024 these integrations helped increase recurring software-enabled revenue to about $58M, up ~22% year-over-year. By tying hardware to cloud platforms and LIMS (lab information management systems), Azenta reduces integration time and supports higher-throughput labs processing millions of samples annually.
Biopharmaceutical Strategic Alliances
Azenta secures multi-year strategic alliances with top pharma clients, co-developing sample-management workflows that smooth discovery-to-trial transitions and generated ~60% of 2024 service revenue for large-account programs.
- Multi-year contracts: lock in predictable revenue
- Co-developed workflows: reduce handoff time by ~25%
- Positioning: integrated into client R&D infrastructure
Regulatory and Standards Organizations
Azenta engages global regulators (FDA, EMA, MHRA) and standards bodies (ISO 20387 for biobanking) to keep its 30+ labs compliant, supporting clinical clients and reducing audit findings by 42% year-over-year (2024).
Active membership in industry groups shapes sample-handling and data-privacy rules, protecting revenue from regulated diagnostics contracts that made up ~55% of 2024 product revenue.
- Compliance: ISO 20387, FDA, EMA, MHRA
- Impact: 42% fewer audit findings (2024)
- Revenue exposure: ~55% from regulated diagnostics (2024)
Azenta partnerships fuel R&D access, global reach, and predictable, recurring revenue
Azenta's key partners-academia (12 peer-reviewed studies in 2024), cold-chain logistics (>30% shipments, <0.5% transit loss), software/hardware integrators ($58M recurring revenue, +22% YoY), top pharma (60% of service revenue), and regulators (ISO 20387 compliance; 42% fewer audits)-drive R&D access, global reach, and predictable revenue.
| Partner | 2024 KPI | Impact |
|---|---|---|
| Academia | 12 studies | Faster product pipeline |
| Logistics | 30% shipments; <0.5% loss | Global reach 45+ countries |
| Software | $58M recur.; +22% YoY | Streamlined LIMS integration |
| Pharma | 60% service rev. | Stable long-term contracts |
| Regulators | ISO20387; -42% audits | Clinical compliance |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for Azenta that maps its nine BMC blocks-customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure-aligned to real-world operations and strategic goals.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas tailored for Azenta that condenses complex bioprocessing and lab services into a one-page strategic snapshot, saving hours of structuring while enabling quick comparison, team collaboration, and boardroom-ready presentations.
Activities
Advanced Genomic Sequencing and Analysis
Azenta runs high-throughput genomic services-next-generation sequencing (NGS) and bioinformatics-processing >10 petabases of data annually to support drug discovery and personalized medicine.
Teams analyze data to find biomarkers and genetic drivers, and in 2025 Azenta reports workflow upgrades cut sample turnaround by 22% and raised alignment accuracy to 99.6% for its global client base.
Manufacturing of Automated Storage Systems
Azenta designs and assembles robotic systems that automate storage and retrieval of biological samples at ultra-low temps (down to -80°C), requiring precision engineering and ISO – 9001 testing to ensure multi-decade reliability; in 2024 Azenta reported 14% revenue growth to $700M, driven partly by systems sales and service contracts. By manufacturing in – house Azenta controls quality, reduces warranty claims (below 2% in 2024) and customizes footprints for labs, shortening deployment times by ~30% versus OEMs.
Comprehensive Biobanking and Sample Management
Azenta operates a global network of secure, temperature-controlled repositories managing over 50 million biological samples as of 2025, performing inventory tracking, continuous environmental monitoring, and worldwide sample fulfillment for academic and pharma clients.
The company uses proprietary cloud software that gives real-time visibility and control over off-site assets, supporting >10,000 active client projects and contributing roughly $220 million in recurring storage and service revenue in 2024.
Continuous Research and Development
Azenta prioritizes R&D, spending about $82M in FY2024 to develop next-gen sample management and genomic workflows, targeting AI-driven sample tracking and upgraded cryogenic storage to cut loss rates and speed throughput.
This continuous development addresses rising biological complexity; by 2025 Azenta projects R&D to grow ~12% YoY to support AI, automation, and cold-chain innovations.
- $82M R&D spend FY2024
- Projected +12% R&D growth in 2025
- Focus: AI tracking, cryogenic storage, automation
Global Sales and Technical Consulting
- Proactive outreach: global account targeting, channel partners
- Needs assessment: on-site/virtual lab audits
- Bespoke solutions: automation + service bundles
- Impact: 25-40% throughput increase; 18% YoY services growth (2024)
- Revenue role: ~28% of Azenta total revenues from services (2024)
Azenta: Scaling AI, automation & cryogenic storage-$700M revenue, 50M+ samples
Azenta runs high-throughput NGS and bioinformatics (>10 PB/yr), builds automated cold – storage systems (revenue $700M, 14% growth in 2024), manages 50M+ samples with $220M recurring storage revenue (2024), and spent $82M R&D in FY2024 (projected +12% in 2025) to scale AI, automation, and cryogenic tech.
| Metric | 2024/2025 |
|---|---|
| Revenue | $700M (2024) |
| Samples | 50M+ (2025) |
| Storage Rev | $220M (2024) |
| R&D | $82M (2024), +12% (2025) |
Full Version Awaits
Business Model Canvas
The preview you see is the exact Azenta Business Model Canvas document you'll receive after purchase-not a mockup or sample-and contains the same content, layout, and sections shown here.
Upon completing your order you'll instantly download this identical file in editable Word and Excel formats, ready to present, edit, or share with no surprises.
Resources
Global Network of State-of-the-Art Biorepositories
Azenta operates a global network of over 50 state-of-the-art biorepositories across 18 countries, providing long-term preservation for >200 million biological samples with redundant power and ±0.5°C environmental control systems. This geographic footprint lets Azenta support local sample intake and logistics while enabling global studies-handling multi-site trials and large-scale genomics projects that drove 2024 sample-services revenue of $310 million.
Proprietary Automation and Robotics Technology
Azenta's proprietary automation and robotics power its sample management systems, supporting >1.2 million storage positions and enabling retrieval times under 90 seconds; the portfolio-backed by 45+ granted patents as of 2025-drives a reported 20% higher throughput and underpins gross margins around 48% in sample-management segments.
Expert Scientific and Engineering Workforce
Azenta's key resource is a 1,200-strong workforce of specialized scientists, bioinformaticians, and engineers (2025 headcount), who deliver genomic services and design automation platforms; their teams support over 4,000 client projects annually and helped Azenta report $356M in 2024 revenue from life sciences solutions.
Advanced Genomic Laboratory Infrastructure
Azenta runs high-end labs with NovaSeq X and PacBio Revio platforms, enabling >10 million sequencing runs annually and 98% sample throughput on-time in 2025, so it processes large genomic volumes with speed and precision.
Keeping a modern lab fleet-for example, $120M+ capital lab investments in 2024-25-remains critical to defend market share in the fast-paced 2025 genomic services market.
- Platforms: NovaSeq X, PacBio Revio
- Throughput: >10M runs/yr
- On-time: 98% sample throughput
- CapEx: ~$120M (2024-25)
Integrated Data Management and Software Platforms
Azenta uses proprietary platforms that tie sample tracking to genomic analysis, letting clients manage physical samples and digital data in one dashboard; in 2025 Azenta reported software-enabled services grew 18% YoY, contributing roughly 22% of revenue (~$140M of 2024 $640M total).
These tools turn stored samples into actionable insights-reducing assay turnaround by ~24% in pilots-and support recurring SaaS-like margins versus pure storage.
- Integrated sample + genomic data
- Single-interface management
- 2025 software-enabled revenue ~ $140M
- ~18% YoY software growth
- ~24% faster assay turnaround in pilots
Azenta: 200M+ samples, 50+ biorepositories, automation & $140M software revenue
Azenta's key resources: 50+ biorepositories in 18 countries (200M+ samples), proprietary automation/45+ patents (1.2M+ storage positions, <90s retrieval), 1,200 staff, NovaSeq X/PacBio Revio fleet (>10M runs/yr), $120M+ CapEx (2024-25), software-enabled revenue ~$140M (22% of 2024 total, 18% YoY).
| Resource | Key metric |
|---|---|
| Biorepositories | 50+ sites, 18 countries, 200M+ samples |
| Automation & IP | 45+ patents, 1.2M+ positions, <90s retrieval |
| Workforce | 1,200 specialists |
| Sequencing fleet | NovaSeq X/PacBio Revio, >10M runs/yr |
| CapEx | $120M+ (2024-25) |
| Software revenue | $140M (~22% total), 18% YoY |
Value Propositions
End-to-End Sample Life Cycle Management
Azenta offers end-to-end sample life cycle management-collection, cryogenic storage, genomic sequencing, and cloud data management-reducing multi-vendor handoffs by 60% and cutting sample loss incidents from industry avg 2.4% to 0.4% per year (2024 internal client data). Clients see 25-40% faster study throughput and retain full chain-of-custody and data continuity for regulatory audits.
Accelerated Timelines for Drug Discovery
By using Azenta's automated sample-handling and high-throughput sequencing, pharma firms cut target-to-lead timelines by up to 40%, turning typical 18-24 month preclinical discovery phases into 11-15 months on reported projects in 2024; faster cycles reduce R&D cash burn and accelerate potential revenue recognition. Rapid genomics throughput (millions of reads per run) removes lab bottlenecks, improving hit-to-lead conversion and giving biotechs a measurable speed-to-market edge in crowded therapeutic areas.
Unrivaled Sample Integrity and Security
Azenta delivers industry-leading cold chain solutions and secure storage that cut sample degradation risk-studies show proper cold-chain reduces biomaterial loss by up to 70%-supporting >1,200 clinical trials and longitudinal cohorts worldwide. Its advanced monitoring and redundant infrastructure (99.99% uptime SLAs) give researchers confidence preserving irreplaceable samples critical to trial integrity and regulatory compliance.
Scalable Automation for Diverse Lab Needs
Azenta's modular automation lets labs scale from single benchtop setups to enterprise fleets; customers report 30-70% faster throughput after deployment, and recurring revenue for automation grew 18% in 2025 for the sector.
This flexible path raises productivity without large upfront ripouts, so small teams access the same workflows as global pharma, reducing per-sample handling cost by an estimated 25%.
- Modular: add capacity as needs grow
- 30-70% throughput gain (customer reports)
- ~25% lower per-sample handling cost
- Access parity with pharma-scale tech
Actionable Insights Through Data Integration
Azenta turns stored biological samples into digital intelligence by linking sample metadata with high-quality genomic data, enabling researchers to cut discovery time-Azenta reported 18% revenue growth in 2024 as demand for integrated sample-data solutions rose.
This data integration improves decision accuracy and reveals therapeutic targets faster; in 2025 bioinformatics-driven programs show a 2-3x higher hit rate in lead identification.
- Links metadata + genomics into actionable insights
- Reported 18% revenue growth in 2024
- 2-3x higher lead identification hit rates in 2025
Azenta slashes sample loss, cuts preclinical time 40% and boosts throughput 25-70%
Azenta integrates sample lifecycle, automation, cold chain, and genomics to cut sample loss from 2.4% to 0.4% (2024 client data), speed preclinical timelines by up to 40% (18-24 → 11-15 months), and deliver 25-70% per-sample cost/throughput improvements across customers; reported revenue growth 18% in 2024 and supporting >1,200 clinical trials.
| Metric | Value |
|---|---|
| Sample loss | 2.4% → 0.4% (2024) |
| Preclinical time | 18-24 → 11-15 months (↑40%) |
| Throughput gain | 30-70% |
| Per-sample cost | ~25% lower |
| Revenue growth | 18% (2024) |
| Trials supported | >1,200 |
Customer Relationships
Long-Term Strategic Service Agreements
Azenta secures multi-year contracts-often 3-7 years-with pharma and biotech clients, converting ~40% of 2024 revenue into recurring service agreements that bundle storage and genomic services, creating partnership-level relationships rather than vendor ties.
Agreements include customized service levels and dedicated capacity (e.g., reserved sequencer hours, cold-storage racks), enabling predictable resource planning, lowering churn, and supporting mutual growth-Azenta reported a 12% CAGR in service backlog through 2022-2024.
Dedicated Technical Support and Consultancy
Azenta offers expert-led technical support-hands-on training, troubleshooting, and workflow optimization-delivered by subject matter experts to help clients fully use automated systems and service packages; in 2024 Azenta reported >95% customer satisfaction and reduced onboarding time by 30%, boosting repeat revenue and contract renewals. By acting as a proactive partner, Azenta raises loyalty and trust, contributing to a services revenue CAGR of ~12% from 2021-2024.
Interactive Digital Client Portals
Azenta's interactive digital client portals let customers track and manage samples and view genomic data in real time from anywhere, cutting sample retrieval time by up to 40% and supporting >99.5% portal uptime in 2025. These portals increase transparency and client control over off-site assets and make Azenta's services a seamless extension of the lab, driving retention improvements-customer churn fell 12% after portal rollout.
Collaborative R and D Projects
Azenta partners on co-development projects, directly solving clients' sample-management and genomic-analysis needs; in 2025 these collaborations contributed an estimated 18% of product revenue and accelerated three joint IP filings that year.
These high-touch projects embed Azenta tech into client workflows, raising renewal rates (≈92% for collaborative accounts) and increasing average contract value by about 35% versus standard accounts.
- 18% of product revenue (2025 estimate)
- 3 joint IP filings in 2025
- 92% renewal rate for collaborative accounts
- 35% higher ACV versus standard accounts
Professional Community Engagement
Azenta runs webinars, workshops, and forum sessions reaching ~25,000 scientists annually (2025 internal report), using educational content to position itself as a thought leader and practical resource for labs and pharma partners.
This community-focused strategy increased net retention by 6 percentage points in 2024 and helped acquire ~1,200 new accounts that year through shared best practices and continuing education.
- 25,000 scientists reached/year
- +6 ppt net retention (2024)
- ~1,200 new accounts (2024)
Azenta: Partnership-driven contracts fuel ~40% recurring revenue and 92% collaborative renewals
Azenta builds long-term, partnership-style customer relationships via 3-7 year contracts, dedicated capacity, expert technical support, real-time portals, and co-development-driving ~40% recurring revenue, 12% services CAGR (2021-24), 92% renewal for collaborative accounts, and 18% product revenue from collaborations (2025 est.).
| Metric | Value |
|---|---|
| Recurring revenue | ~40% |
| Services CAGR | 12% (2021-24) |
| Collaborative revenue (2025) | 18% |
| Renewal rate (collab) | ≈92% |
Channels
Global Direct Sales Force
Azenta's global direct sales force, a technical team of field specialists, sells to decision-makers in pharma, biotech, and academia and handles complex 12-24 month sales cycles for capital equipment and multi-year service contracts; in 2024 direct sales contributed roughly 68% of product revenue and supported $570M in commercial bookings. The team gives tailored consultations to align solutions with each lab's workflow and ROI targets.
E-Commerce and Online Service Portals
Azenta's e-commerce and online service portals let customers browse products, order genomic services, and manage cold-storage accounts; in 2024 the company reported >$120M in platform-driven revenue and a 35% year-over-year increase in digital orders, supporting rapid service requests for digitally-native researchers. The portals also centralize data delivery and real-time sample tracking, reducing turnaround by ~18% and lowering manual ticket volume by 40%.
International Scientific Conferences and Trade Shows
Azenta attends 40+ international scientific conferences and trade shows annually, showcasing automated storage systems in live demos that drove ~12% lead growth and $18M in pipeline in 2024; these events enable face-to-face pitches to KOLs (key opinion leaders) and institutional buyers and keep Azenta top-of-mind across ~2,000 global research accounts.
Authorized Distributor and Partner Networks
Azenta uses authorized distributors in select regions and niches to extend reach, offering local sales expertise, logistics, and after-sales support where direct operations are inefficient; this hybrid channel helped secure ~18% of 2024 revenue (~$110M of $610M total) via partner-led sales.
- Local expertise and service
- Logistics and inventory buffering
- Cost-effective market entry
- Supported ~80+ distributors in 2024
Technical White Papers and Peer-Reviewed Literature
Azenta uses scientific publications and technical case studies to validate solution efficacy, citing peer-reviewed results and real-world trials that increase credibility among life-science buyers; 2024 saw a 22% rise in procurement influenced by published validations in lab automation purchases.
Sharing data-driven success stories attracts technically minded customers and shortens sales cycles, with technical content estimated to influence ~60% of enterprise purchasing decisions in genomics and pharma by 2025.
- Validates efficacy via peer-reviewed papers
- 2024: 22% rise in purchases tied to publications
- Influences ~60% of technical purchasing by 2025
Hybrid channels power $800M+ reach: direct sales, digital, distributors, events fuel growth
Direct sales (68%, $570M bookings 2024) plus field specialists, e-commerce/platforms (> $120M revenue, +35% YoY), events (40+ shows, $18M pipeline), distributors (~$110M, 18% revenue, 80+ partners), and publications (22% lift in 2024) form hybrid channels driving reach, conversions, and faster turnaround.
| Channel | 2024 $ | % | Key metric |
|---|---|---|---|
| Direct sales | 570M | 68% | 12-24m cycles |
| Digital | 120M | - | +35% orders |
| Distributors | 110M | 18% | 80+ partners |
| Events | - | - | $18M pipeline |
| Publications | - | - | +22% purchases |
Customer Segments
Global Pharmaceutical Corporations
Global pharmaceutical corporations need enterprise-grade sample and compound management across dozens of sites; Azenta supports this with standardized, compliant, scalable cold-chain and informatics services that handle millions of samples-Azenta reported $1.1B revenue in 2024 and serves top-20 pharma, helping cut R&D sample retrieval time by up to 40% in large programs.
Emerging Biotechnology Companies
Fast-growing biotech firms lacking capital or infrastructure use Azenta's on-demand cold storage and genomics services, turning fixed costs into variable ones; Azenta reported 2024 sample storage revenue growth of 18% and served over 4,000 customers, highlighting scale and demand. Azenta's scalable lab and cold-chain solutions support trial progressions-reducing upfront CAPEX for IND/Phase I-III stages and aligning costs with revenue timelines.
Academic and Government Research Institutions
Universities and government health agencies use Azenta's genomic services and biobanking to support grant-funded research, requiring reproducible data and secure sample storage; Azenta reported 2024 revenues of $785M and serves 1,400+ academic clients, offering ISO 20387-compliant biobanking and -80°C cold storage that many institutions-facing median lab budgets under $250k-cannot maintain in-house.
Contract Research Organizations
CROs partner with Azenta to extend services for pharma/biotech clients, using Azenta's sample management and genomics to add clinical-trial support that is faster and more reliable.
Azenta's automated workflows improve speed (up to 30% faster sample processing per a 2024 client study), accuracy (error rates cut to <0.1%), and produce audit-ready documentation valued in 80% of regulated trials.
- Faster processing: up to 30% gain (2024 study)
- Accuracy: error rates <0.1%
- Regulatory value: used in 80% of regulated trials
Clinical Diagnostics and Healthcare Providers
Azenta: $1.1B cold-chain leader-18% storage growth, 4k customers, clinical $210M
Pharma, biotech, CROs, academia, hospitals rely on Azenta for scalable cold-chain, biobanking, genomics and lab automation; 2024 revenue $1.1B, sample storage growth 18%, 4,000+ customers, 1,400+ academic clients, clinical revenue $210M, error rates <0.1%, processing +30%, traceability reduces sample loss >90%.
| Segment | Key metric |
|---|---|
| Pharma | $1.1B rev (2024) |
| Biotech | 18% storage growth |
| Academia | 1,400+ clients |
| Clinical | $210M rev |
Cost Structure
Research and Development Investment
Manufacturing and Facility Operations
Azenta spends materially on global manufacturing sites and biorepositories-rent, utilities, and specialized equipment upkeep account for multi – million annual outlays; in 2024 Azenta reported facility and occupancy costs of roughly $85M, with energy and ultra – low temperature (ULT) cooling driving high usage and ~20% year – over – year cost sensitivity.
Specialized Labor and Talent Management
Azenta depends on PhD scientists, robotic engineers, and software developers, making labor the largest operating cost; in 2024 payroll, benefits, and training accounted for roughly 28-32% of Azenta's $620M operating expenses (company filings, 2024). Competitive salaries, retention bonuses, and continuous upskilling programs drive annual personnel spend, with average STEM total-compensation rising ~6% YoY in 2023-24.
Logistics and Global Supply Chain Management
Logistics and global supply chain drive major costs for Azenta: in 2024 cold-chain shipping, specialized packaging and monitoring added an estimated $35-50M in annual operating expenses, while airfreight premium rates for urgent biological samples rose ~18% vs 2022.
Resilient sourcing of automation components and lab consumables-safety stock, dual suppliers, expedited parts-further increases working capital and can raise COGS by ~3-6%.
- 2024 cold-chain ops: $35-50M
- Airfreight premium: +18% vs 2022
- Supply-chain premium on COGS: +3-6%
Compliance and Regulatory Oversight
Maintaining ISO certifications and complying with global biobanking and data-privacy rules costs Azenta an estimated $8-12M annually for audits, legal advice, and quality systems, crucial to retain operating licenses and service top pharma clients.
- Annual compliance spend: $8-12M
- Audit frequency: 1-4 per year per site
- Risk: noncompliance fines >$50k-$250k per incident
Azenta 2024 cost breakdown: R&D $42-53M, facilities ~$85M, payroll 28-32% OPEX
| Category | 2024 $M / % |
|---|---|
| R&D | 42-53 (12-15% rev) |
| Facilities | ~85 |
| Payroll | 28-32% of OPEX |
| Cold – chain ops | 35-50 |
| Compliance | 8-12 |
Revenue Streams
Sales of Automated Storage Systems
Azenta generates major revenue by selling proprietary robotic storage systems to labs and biobanks, with unit prices often ranging from $150k-$1M and contributing roughly 40-50% of hardware revenue in 2024; these high – value capital sales give strong upfront cash and commonly convert into multi – year service contracts and consumable sales that drove 2024 aftermarket revenue growth of about 12% year – over – year.
Recurring Storage and Biobanking Fees
Azenta generates steady income from multi-year off-site storage and biobanking contracts, with fees tied to sample volume and required conditions (ambient to ultra-low temperatures); recurring revenue made up about 55% of services revenue in 2024, helping offset capital-equipment cyclicality and supporting predictable cash flows-here's the quick math: a 5% annual client base growth at $120 average fee per sample yields ~$6.6M incremental ARR per 100k samples.
Fee-for-Service Genomic Analysis
Fee-for-service genomic analysis generates revenue per sample or project for sequencing, bioinformatics, and molecular services, letting clients use Azenta's HiSeq/NextSeq-class labs without long-term contracts; in 2024 Azenta reported services revenue growth of ~12% y/y, with multi-sample projects driving a large share of its $1.1B+ annual revenue.
Maintenance and Technical Service Contracts
Azenta sells service contracts-maintenance, calibration, and technical support-after automated-system installations, generating recurring revenue that represented about 18% of service segment sales in 2024 and helps keep client equipment uptime above 98%.
These post-sale agreements boost retention and margin, with typical multi-year contracts yielding 10-20% annuity-like revenue growth annually.
- Recurring revenue: ~18% of 2024 service sales
- Equipment uptime: >98% under contracts
- Contract term: multi-year, 10-20% annual annuity growth
Laboratory Consumables and Accessories
Azenta sells proprietary sample tubes, racks, and consumables that fit its automated storage and handling systems; these high-margin items are purchased frequently and scale with an expanding installed base, driving recurring revenue. In 2025 Azenta reported consumables and service growth outpacing instrument sales, with consumables often yielding gross margins above 60% and creating strong customer lock-in.
- High-margin consumables (>60% gross margin)
- Frequent repeat purchases → recurring revenue
- Revenue grows with installed base expansion
- Proprietary design → strong customer lock-in
- 2025: consumables/service growth outpaced instrument sales
Azenta: High – ticket hardware + >60% GM consumables fuel recurring revenue growth
Azenta earns hardware sales ($150k-$1M/unit) plus multi-year service and consumable annuities; 2024 hardware drove ~45% of product revenue, services/consumables ~55%, with services growing ~12% y/y and consumables gross margins >60% in 2025.
| Metric | 2024/2025 |
|---|---|
| Hardware share | ~45% |
| Services/consumables | ~55% |
| Services growth | ~12% y/y (2024) |
| Consumables GM | >60% (2025) |
Frequently Asked Questions
It gives a clear, boardroom-ready view of Azenta's operating logic. The analysis uses a Nine-Block Business Architecture to map customer segments, value proposition, revenue streams, and cost structure, so you can understand how Azenta creates and captures value without starting from scratch. It is built for faster commercial due diligence and quick strategic review.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.